You are here: Industry Insights > Allergy Therapeutics

News List

Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate pharmatimes
January 07, 2021
Allergy Therapeutics has initiated a biomarker study at Imperial College London, which will aim to evaluate its novel virus like particle (VLP) based peanut allergy vaccine candidate.
Positive Phase I results for Allergy’s Acarovac pharmatimes
May 21, 2019
Allergy Therapeutics announced positive Phase I safety and tolerability results of its subcutaneous Acarovac MPL (Monophosphoryl Lipid A). The results were in patients with house dust mite-induced allergic rhinoconjunctivitis.
Allergy Therapeutics’ birch pollen product fails to meet primary endpoint pharmaceutical-technology
March 20, 2019
UK-based Allergy Therapeutics has announced that its new adjuvanted allergoid product indicated for birch pollen-induced seasonal allergic rhinitis failed to meet the primary endpoint in the Phase III B301 trial.
Setback for Allergy’s birch pollen immunotherapy drugs
March 19, 2019
Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.